

**South East London Integrated Medicines Optimisation Committee
(SEL IMOC)**

**Withdrawal of formulary recommendation number 066 (issued
May 2017):**

**Clofazimine in combination with clarithromycin and rifabutin as
anti-MAP (*Mycobacterium avium* subspecies *paratuberculosis*)
therapy for the treatment of Crohn's disease in adults**

Following advice from the specialist Inflammatory Bowel Disease (IBD) sub-group of the SEL IMOC, the Committee has agreed to withdraw this formulary recommendation. This is because there are now more clinically effective treatments available for the management of Crohn's disease in adults.

Clofazimine in combination with clarithromycin and rifabutin as anti-MAP therapy for the treatment of Crohn's disease in adults is no longer recommended for prescribing in SEL.

Patients who started their 2 year course before this withdrawal recommendation was issued are able to continue treatment until they or their NHS clinician consider it appropriate to stop or until their course is completed.

The SEL Inflammatory Bowel Disease (IBD) treatment pathways can be found [here](#).

February 2023